Buclizine

證據等級: L5

預測適應症: 0 個

Buclizine: Repurposing Assessment — Insufficient Data to Proceed

One-Sentence Summary

Buclizine (DB00354) is a DrugBank-registered compound for which the current evidence pack contains no original indication records and no TxGNN-predicted new indications. A full repurposing evaluation cannot be completed at this stage. Recommended Decision: Hold — critical data must be resolved before further assessment.

Quick Overview

Item	Content
Original Indication	Not available in current data
Predicted New Indication	No predictions generated
TxGNN Prediction Score	Not available
Evidence Level	L5 — no actual studies; prediction pipeline did not produce results
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why No Prediction Is Available

The TxGNN prediction pipeline returned an empty result set for Buclizine. Two plausible causes are:

DrugBank mapping gap: If Buclizine (DB00354) could not be confidently placed in the TxGNN knowledge graph — for example, due to missing or ambiguous node embeddings — the model would produce no scored candidates.
Missing MOA anchor: Without a confirmed mechanism of action, the knowledge-graph traversal has no reliable starting edges from which to propagate repurposing signals.

In addition, no original indication text is present in the evidence pack. Without knowing what Buclizine was approved to treat, it is not possible to contextualise any future prediction or assess mechanistic plausibility.

Currently, detailed mechanism of action data is not available. Based on known information, Buclizine belongs to the piperazine-class antihistamines; however, this has not been confirmed by the DrugBank API query and should not be relied upon for clinical decision-making without verification.

South Africa Market Information

Buclizine holds no SAHPRA registrations and is currently not marketed in South Africa. There are no approved dosage forms, approved indications, or registration numbers to report.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack is structurally incomplete — the TxGNN model produced no predicted indications, original indication data is absent, and mechanism of action information was not retrieved. A repurposing evaluation cannot be conducted without these foundations.

To proceed, the following is needed:

TxGNN re-run: Confirm that DB00354 maps to a valid knowledge-graph node; re-execute prediction and verify that predicted_indications is populated
MOA retrieval: Query the DrugBank API for Buclizine’s pharmacodynamics, targets, and mechanism of action (currently flagged as a High-severity data gap)
Original indication data: Retrieve approved indication text from SAHPRA, the British National Formulary, or WHO INN records to establish the repurposing baseline
Regulatory PI review: Download the SAHPRA-approved Professional Information (or equivalent international label) to populate warnings, contraindications, and drug-interaction fields (currently flagged as a Blocking data gap)
South Africa market feasibility: Given zero current SAHPRA registrations, a new registration pathway would be required if any repurposing indication were ultimately supported — this regulatory timeline should be scoped early

This report was generated from Evidence Pack TW-DB00354-multi (v4, data cut-off 2026-04-04). Results are for research reference only and do not constitute medical advice. All repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.